Trial Profile
Phase II Study of Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 May 2019
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- 11 May 2017 New trial record